Clinical studyLow-molecular-weight heparins and unfractionated heparin in the treatment of patients with acute venous thromboembolism: Results of a meta-analysis
References (62)
- et al.
Safety and efficacy of warfarin started early after submassive venous thrombosis or pulmonary embolism
Lancet
(1986) - et al.
Low molecular weight heparin
Blood
(1992) - et al.
Low molecular weight heparin (Kabi 2165 Fragmin); pharmacokinetics after intravenous and subcutaneous administration in human volunteers
Thromb Res
(1986) - et al.
Bioavailability and antagonization of the low molecular weight heparin CY 216 in man
Thromb Res
(1986) - et al.
Laboratory monitoring of the clinical effects of low molecular weight heparin
Thromb Res
(1991) - et al.
Anticoagulant and antithrombotic effects of heparin and low molecular weight heparin fragment in rabbits
Thromb Res
(1982) - et al.
The relationship between the haemorrhagic and antithrombotic properties of low molecular weight heparin in rabbits
Blood
(1982) - et al.
Subcutaneous treatment of deep vein thrombosis with low molecular weight heparin. A dose finding study with LMWH-NOVO
Thromb Res
(1989) - et al.
Comparison of subcutaneous low molecular weight heparin with intravenous standard heparin in proximal deep vein thrombosis
Lancet
(1992) - et al.
Incorporating variations in the quality of individual randomized trials into meta-analysis
J Clin Epidemiol
(1992)
Lower mortality in cancer patients treated with low molecular weight versus standard heparin
Lancet
Warfarin sodium versus low-dose heparin in the long term treatment of venous thrombosis
NEJM
Continuous intravenous heparin compared with intermittent subcutaneous heparin in the initial treatment of proximal vein thrombosis
NEJM
Effect of heparin and heparin fractions on platelet aggregation
J Clin Invest
Pharmacotherapeutic aspects of unfractionated and low molecular weight heparin
Drugs
Anticoagulant properties of heparin fractionated by affinity chromatography on matrix-bound antithrombin III and by gel filtration
Thromb Res
Anticoagulant effects of two types of low molecular weight heparin administered subcutaneously
Thromb Res
Low molecular weight heparin: is small beautiful?
NEJM
Treatment of established venous thromboembolism with enoxaparin: preliminary report
Acta Chir Scand
An open trial of enoxaparin in thé treatment of deep vein thrombosis of the leg
Haemostasis
Treatment of deep venous thrombosis with a very low molecular weight heparin (CY 222)
Haemostasis
Treatment of acute pulmonary embolism by a low molecular weight heparin fraction: a preliminary study
Intensive Care Med
Fragmin once or twice daily subcutaneously in the treatment of deep vein thrombosis of the leg
Thromb Res
Subcutaneous low molecular weight heparin compared with continuous intravenous heparin in the treatment of proximal vein thrombosis
NEJM
Randomized trial of subcutaneous LMWH CY 216 (fraxiparine) compared with intravenous unfractionated heparin in the curative treatment of submassive pulmonary embolism. A dose ranging study
Circulation
A Collaborative European Multicentre Study. A randomized trial of subcutaneous low molecular weight heparin (CY 216) compared with intravenous unfractionated heparin in the treatment of deep vein thrombosis
Thromb Haemost
Fragmin once daily subcutaneously in a fixed dose compared with continuous intravenous unfractionated heparin in the treatment of deep vein thrombosis
Thromb Haemost
Subcutaneous low molecular weight heparin versus subcutaneous unfractionated heparin in the treatment of deep vein thrombosis: a Polish multicenter trial
Thromb Haemost
Subcutaneous fixed dose of enoxaparin versus intravenous adjusted dose of unfractionated heparin in the treatment of deep vein thrombosis
Arch Intern Med
Two daily subcutaneous injections of Fragmin as compared with intravenous standard heparin in the treatment of deep vein thrombosis
Thromb Haemost
Un nouveau treatment des thromboses veineuses profondes: les fractions d'heparine de bas poids moleculaire
Presse Med
Cited by (445)
Early detection of the existence or absence of the treatment effect: A cumulative meta-analysis
2020, Journal of Clinical EpidemiologyRepurposing of drugs approved for cardiovascular diseases: Opportunity or mirage?
2020, Biochemical PharmacologyDeep Venous Thrombosis
2018, Essentials of Physical Medicine and Rehabilitation: Musculoskeletal Disorders, Pain, and RehabilitationInternational clinical practice guidelines including guidance for direct oral anticoagulants in the treatment and prophylaxis of venous thromboembolism in patients with cancer
2016, The Lancet OncologyCitation Excerpt :As presented in the 2013 CPGs,20 data pooled from randomised and retrospective studies indicated that patients with cancer who were initially treated with unfractionated heparin or low-molecular-weight heparin (LMWH) followed by a vitamin K antagonist (VKA) have a high prevalence of VTE recurrence (10·0–38·0% for unfractionated heparin and 6·7–17·0% for LMWH) and major bleeding (6·3–35·0% and 2·9–16·9%, respectively). With regard to recommendations for short-term LMWH versus short-term unfractionated heparin followed by VKA, the 2013 CPGs were based on several meta-analyses27–35 of subgroups of patients with cancer comparing short-term LMWH, unfractionated heparin, or fondaparinux in the initial treatment of VTE in the general population. Since our previous recommendations, two meta-analyses36,37 have compared short-term LMWH with unfractionated heparin in patients with cancer.
The effect of therapeutic anticoagulation on overall survival in men receiving first-line docetaxel chemotherapy for metastatic castration-resistant prostate cancer
2015, Clinical Genitourinary CancerCitation Excerpt :Prandoni et al first demonstrated the survival benefit of LMWH compared with unfractionated heparin in patients with cancer and VTE (without differences in recurrence rates of VTE).34 Survival benefits of LMWH in patients with VTE have been further validated by subsequent meta-analyses,35,36 which has led to several randomized controlled trials to specifically assess the survival benefit of LMWH in patients without VTE. FAMOUS (Fragmin Advanced Malignancy Outcome Study), which randomized 385 patients with various advanced cancers to receive either dalteparin or placebo for 12 months, showed a nonsignificant trend toward a survival advantage in the group treated with dalteparin.23
Heparins and cancer survival: Where do we stand?
2014, Thrombosis Research
- 1
Dr. Sergio Siragusa is a recipient of a Grant for Thrombosis Research from IRCCS Policlinico S. Matteo, Pavia, Italy.
- 2
Dr. Hirsh is a Distinguished Professor of the Heart and Stroke Foundation of Canada.
- 3
Dr. Ginsberg is a recipient of a Research Scholarship of the Heart and Stroke Foundation of Canada.